Amicus Therapeutics (FOLD 0.82%) saw its excellent 2012 performance cut in half today, as shares that had been up 70% for the year fell 45% in a single day. The fall came on news that the company's lead drug, called migalastat, which was designed to treat Fabry disease, failed to meet its primary endpoint in its phase 3 trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn break down this news, and discuss where Amicus and GlaxoSmithKline (GSK 0.35%), with whom Amicus was partnered on the compound, can go from here.
Why Shares of Amicus Cratered Today
By Max Macaluso and Brenton Flynn – Dec 20, 2012 at 5:45PM
NASDAQ: FOLD
Amicus Therapeutics
Market Cap
$2.6B
Today's Change
(-0.82%) $0.07
Current Price
$8.48
Price as of October 23, 2025 at 3:55 PM ET
The biotech space is full of roller coasters, and Amicus is the latest.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo